ClinVar Miner

Submissions for variant NM_000527.5(LDLR):c.660del (p.Asp221fs)

dbSNP: rs875989905
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
LDLR-LOVD, British Heart Foundation RCV000211699 SCV000294857 pathogenic Hypercholesterolemia, familial, 1 2016-03-25 criteria provided, single submitter literature only
Labcorp Genetics (formerly Invitae), Labcorp RCV000824495 SCV000965394 pathogenic Familial hypercholesterolemia 2021-02-10 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. This variant has been observed in several individuals affected with familial hypercholesterolemia (PMID: 9678702, 11139254, 22883975, 11462246, 15556094). This variant is also known as P199fsX243, 657delC. ClinVar contains an entry for this variant (Variation ID: 226330). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Asp221Thrfs*44) in the LDLR gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LDLR are known to be pathogenic (PMID: 20809525, 28645073).
Brunham Lab, Centre for Heart and Lung Innovation, University of British Columbia RCV000211699 SCV001432618 pathogenic Hypercholesterolemia, familial, 1 2019-05-11 criteria provided, single submitter research
Ambry Genetics RCV002363057 SCV002664460 pathogenic Cardiovascular phenotype 2023-12-13 criteria provided, single submitter clinical testing The c.660delC (p.D221Tfs*44) alteration, located in exon 4 (coding exon 4) of the LDLR gene, consists of a deletion of one nucleotide at position 660, causing a translational frameshift with a predicted alternate stop codon after 44 amino acids. Frameshift alterations are typically deleterious in nature (Richards, 2015). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This mutation (also described as c.657delC) has been reported in numerous familial hypercholesterolemia (FH) cohorts from a variety of ethnic backgrounds (Lee, 1998; Bochmann, 2001; Laurie, 2004; Bamimore, 2015; Hu, 2016). Based on the available evidence, this alteration is classified as pathogenic.
GeneDx RCV003235135 SCV003933319 pathogenic not provided 2022-12-14 criteria provided, single submitter clinical testing Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 34037665, 9678702)
Cardiovascular Genetics Laboratory, PathWest Laboratory Medicine WA - Fiona Stanley Hospital RCV000211699 SCV000268575 pathogenic Hypercholesterolemia, familial, 1 2014-05-05 no assertion criteria provided clinical testing
Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, Academisch Medisch Centrum RCV000211699 SCV000606183 pathogenic Hypercholesterolemia, familial, 1 no assertion criteria provided research
Natera, Inc. RCV000824495 SCV002086377 pathogenic Familial hypercholesterolemia 2020-12-07 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.